PT  - JOURNAL ARTICLE
AU  - Helwick, Caroline
ED  - Hida, Toyoaki
TI  - Sequential Therapy with Gefitinib for Advanced Non-Small Cell Lung Cancer
DP  - 2008 Aug 01
TA  - MD Conference Express
PG  - 13--14
VI  - 8
IP  - 4
4099  - http://mdc.sagepub.com/content/8/4/13.2.short
4100  - http://mdc.sagepub.com/content/8/4/13.2.full
AB  - In previous studies, gefitinib combined with chemotherapy has provided no survival gain compared with chemotherapy alone for patients with advanced non-small cell lung cancer (NSCLC). However, a phase 3 trial has shown that sequential therapy with gefitinib may offer clinical benefit after platinum-based doublet chemotherapy in this setting. The West Japan Thoracic Oncology Group trial [WJTOG 0203; NCT00144066] involved patients who were randomly assigned to 3–6 cycles of chemotherapy alone (298 patients) or to 3 cycles of chemotherapy followed by daily gefitinib until disease progression (300 patients).